⌘K

07:30:00·895d

PRReleasevia Quantisnow

Twist Bioscience Reports Fiscal Fourth Quarter and Full Year Fiscal 2023 Financial Results

ByQuantisnow·Wall Street's wire, on your screen.

TWST· Twist Bioscience Corporation

Health Care

Quantisnowquantisnow.com

Quantisnow streams SEC filings, FDA approvals, analyst ratings, insider trades, and press releases to retail investors in real time. This insight was curated and delivered from the Quantisnow live feed.

Companies

TWST
Twist Bioscience Corporation
Health Care

Recent analyst ratings

Nov 4UpdateStephens$41.00
Dec 13UpdateWolfe Research$60.00
Jun 4UpdateGuggenheim$53.00
Jan 17UpdateGoldman$45.00
Sep 27UpdateBerenberg$27.00
Jan 5UpdateScotiabank$33.00

Related

INSIDER1d
Director Starovasnik Melissa A. sold $30,915 worth of shares (500 units at $61.83) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 25,222 units (SEC Form 4)
INSIDER3d
President and COO Finn Patrick John sold $141,026 worth of shares (2,321 units at $60.76), decreasing direct ownership by 0.82% to 281,808 units (SEC Form 4) to cover withholding tax
INSIDER7d
Chief Executive Officer Leproust Emily M. exercised 9,671 shares at a strike of $8.82 and sold $630,957 worth of shares (9,671 units at $65.24) as part of a pre-agreed trading plan (SEC Form 4)
INSIDER9d
SEC Form 4 filed by Laponis Adam
PR9d
Twist Bioscience to Report Fiscal 2026 Second Quarter Financial Results on Monday, May 4, 2026
INSIDER14d
SEC Form 4 filed by Laponis Adam
INSIDER17d
SEC Form 4 filed by Laponis Adam
SEC21d
SEC Form 144 filed by Twist Bioscience Corporation